ENGOT-ov43/keylynk-001: A phase III, placebo- and active-controlled trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of advanced BRCA-nonmutated epithelial ovarian cancer

Authors :: R.L. Coleman
K. Fujiwara
J. Sehouli
V. Salutari
P. Zola
R. Madry
J. Korach
P. Pautier
D. Cibula
S. Lheureux
K. Hasegawa
B.G. Kim
C.H. Lai
A. Gonzalez-Martinez
Q. Liu
S. Keefe
M. Puglisi
S. Topuz
B.J. Monk
R.C. Arend
D.M. O'Malley
I. Vergote
Source :: Gynecologic Oncology. 159:89-90
Publication Year :: 2020
Publisher :: Elsevier BV, 2020.

Tools